Hims & Hers Health, Inc. $HIMS Shares Purchased by M&T Bank Corp

Key Points

• M&T Bank Corp boosted its stake in Hims & Hers by 1,226.9% in Q4, buying 140,920 shares to own 152,406 shares (about 0.07% of the company) worth roughly $4.95 million.
• Hims & Hers beat Q4 EPS estimates ($0.08 vs. $0.02) with revenue of $617.8 million (up 28.4% year‑over‑year), though revenue narrowly missed analyst expectations.
• The company is expanding prescription weight‑loss and women’s care offerings (including Eli Lilly GLP‑1 access) and has drawn positive institutional attention (JPMorgan initiated Overweight), but significant insider selling and new competition from Amazon pose near‑term risks.

M&T Bank Corp raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 1,226.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 152,406 shares of the company's stock after buying an additional 140,920 shares during the quarter. M&T Bank Corp owned approximately 0.07% of Hims & Hers Health worth $4,949,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of HIMS. Quent Capital LLC purchased a new stake in Hims & Hers Health in the third quarter valued at approximately $28,000. Binnacle Investments Inc acquired a new position in shares of Hims & Hers Health in the 3rd quarter valued at $28,000. Silicon Valley Capital Partners purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at $48,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter worth $28,000. Finally, Smartleaf Asset Management LLC raised its position in shares of Hims & Hers Health by 44.7% in the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company's stock worth $54,000 after buying an additional 283 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Trading Up 0.2%

Shares of HIMS opened at $30.62 on Monday. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The stock's 50-day moving average is $20.98 and its two-hundred day moving average is $31.18. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The stock has a market cap of $6.98 billion, a PE ratio of 60.04, a P/E/G ratio of 2.89 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company's revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.11 earnings per share. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.61 earnings per share for the current fiscal year.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Expanded Lilly partnership — HIMS expanded its platform to let clinicians prescribe Eli Lilly GLP‑1 products (Zepbound, KwikPen, Foundayo) with fulfillment via LillyDirect, widening its weight‑management offering and creating a clearer prescription revenue path. Article Title
• Positive Sentiment: JPMorgan initiation — JPMorgan initiated coverage with an Overweight rating and $35 price target, framing the Novo Nordisk partnership and broader GLP‑1 access as a potential turning point; that institutional endorsement lifted sentiment. Article Title
• Positive Sentiment: Product expansion into women’s care — HIMS is scaling menopause/perimenopause offerings (including estrogen patches) and boosting peptide capabilities, which broadens recurring‑care revenue streams beyond legacy DTC categories. Article Title
• Neutral Sentiment: Regulatory tailwind but with open questions — The FDA scheduled a July compounding advisory committee meeting on certain peptides; the market views this as validating peptide opportunity but outcome/timing remain uncertain. Article Title
• Neutral Sentiment: Analyst/target moves — Bank of America raised its target to $32 (Neutral) and several other shops have adjusted coverage; upgrades add support but consensus remains mixed, so analyst activity amplifies swings rather than resolving execution risk. Article Title
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe and other insiders sold shares under Rule 10b5‑1 plans (SEC filings), which can sap near‑term sentiment despite being pre‑arranged. Article Title
• Negative Sentiment: Competitive pressure — Amazon’s entry into GLP‑1/weight‑loss programs and other deep‑pocket competitors raise concerns about margin pressure and share erosion in a key growth category. Article Title

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. BTIG Research downgraded Hims & Hers Health from a "buy" rating to a "neutral" rating in a research report on Tuesday, February 24th. Truist Financial reiterated a "hold" rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Citigroup upgraded shares of Hims & Hers Health from a "sell" rating to a "neutral" rating and raised their price target for the company from $13.25 to $24.00 in a report on Tuesday, March 10th. Leerink Partners lifted their price target on shares of Hims & Hers Health from $17.50 to $25.00 and gave the company a "market perform" rating in a research report on Monday, March 16th. Finally, Barclays boosted their price objective on shares of Hims & Hers Health from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 11th. Four research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $32.53.

Insider Buying and Selling

In other news, COO Michael Chi sold 97,289 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the transaction, the chief operating officer directly owned 407,282 shares of the company's stock, valued at approximately $10,055,792.58. The trade was a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Irene Becklund sold 5,529 shares of the company's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the transaction, the insider owned 8,752 shares of the company's stock, valued at $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 204,857 shares of company stock worth $5,285,706 in the last 90 days. 17.71% of the stock is owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.